Clinical trial · Interventional
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study
NCT01995240CI-TRIAL-00026515REMPcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at an early stage. Preferably, these markers could be determined non-invasively and provide insight into the biology of pancreatic cancer. Several MR techniques can serve for this purpose. However, optimalisation of these techniques is needed and their reproducibility should be assessed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gadobutrol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Optimization
- description
- For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2\* MRI and DWI MRI scan.
- interventionNames
- Drug: Gadobutrol
- type
- EXPERIMENTAL
- label
- Reproducibility
- description
- For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2\* MRI and DWI MRI scans within one week.
- interventionNames
- Drug: Gadobutrol
Primary outcomes (1)
- measure
- Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pancreatic tumors, with histological or cytological proof of adenocarcinoma or a high suspicion on CT imaging. * Any tumor with a size ≥ 1cm * WHO-performance score 0-2 * Written informed consent Exclusion Criteria: * Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol. * Contra-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; or an aneurysm clip in their brain; patients with severe claustrophobia. * Renal failure (GFR \< 30 ml/min) hampering safe administration of Gadolinium containing MR contrast agent. * For the reproducibility part of the protocol: surgery, radiation and/or chemotherapy foreseen within the timeframe needed for MRI scanning.
References
Publications (0)
Data not yet available
No reference posted for this study.